Fosamprenavir Calcium (Fosamprenavir Calcium) Patent Expiration, LOE Window & CMS Spending

Fosamprenavir Calcium (Fosamprenavir Calcium) by Viatris: Multi-Source Generic Molecule, 2 AB generics, $1.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorViatris
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$1.5M
2024 Medicare Part D Spend$1.4M
2024 Medicaid Spend$140K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.